Startup profile for Aiforia: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Aiforia funding, valuation and investors

European institutional financing for ai-assisted pathology and cancer detection.

Verified company research · funding, investors and latest developments

Keep track of Aiforia

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

EIB financing

€20M · August 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

public

public · Helsinki, Finland

Sources: latest funding · eib.org Last verified: 2026-08-18

Overview

Aiforia is associated with European institutional financing for AI-assisted pathology and cancer detection. On 2026-08-09, it announced €20M in EIB financing. Undisclosed valuation, revenue and financing terms are not inferred.

Why Aiforia is interesting

August 2026: €20M in EIB financing, with the financing type preserved rather than flattened into a generic VC total.

Key facts

  • EIB financing: €20M (August 2026)
  • Financing classification: EIB financing
  • Undisclosed terms remain undisclosed

Funding history (newest first)

EIB financing

2026-08 €20M

Source: Read source · eib.org

Market / IPO context

Editorial / static context — not a live quote.

FAQs about Aiforia

Practical answers founders, operators, and investors typically search for.

European institutional financing for ai-assisted pathology and cancer detection.
€20M in EIB financing, announced in August 2026.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.